Dr. Martens’ main shareholder sells down its stake
IngreLux, a Luxembourg company owned by funds advised by the investment firm Permira, has sold 65 million ordinary shares in Dr. Martens at a price of 395 pence (€4.73-$5.35) each in a placing, raising gross proceeds of approximately £257 million (€307.7m-$347.8m). The price represents a 6 percent discount from the ...
SIGN-IN if you are already a subscriber of Shoe Intelligence.
Subscribe today
Your membership benefits:
- Unlimited access to shoeintelligence.com - all insight, analysis and statistics 24h/day available online
- Our executive edition of Shoe Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Unlimited access to shoeintelligence.com - all insight, analysis and statistics 24h/day available online
- Powerful search and access to over 16,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Organisation-wide access across offices, people and devices
To continue reading this article REGISTER NOW.